A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2014
At a glance
- Drugs LY 3007113 (Primary)
- Indications Lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 15 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
- 12 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Mar 2013 Planned number of patients changed from 85 to 36 as reported by ClinicalTrials.gov.